Corporate Profile

Gamida Cell is a clinical-stage biopharmaceutical company committed to developing novel cell therapies with the potential to cure difficult-to-treat cancers and rare, serious hematologic diseases. We are leveraging our proprietary nicotinamide-based cell expansion technology, or NAM technology, to develop product candidates designed to address the limitations of cell therapies.

Copyright West LLC. Minimum 15 minutes delayed.

Latest News

View All
Jan 22, 2019

Gamida Cell and Be The Match BioTherapies® Announce Strategic Collaboration

Read More
Jan 07, 2019

Gamida Cell Announces 2019 Goals and Provides Company Update

Read More
Dec 04, 2018

Gamida Cell Announces Publication of Phase 1/2 Clinical Data of NiCord® in the Journal of Clinical Oncology

Read More
Dec 03, 2018

Gamida Cell Reports Immune Reconstitution Data from Completed Phase 1/2 Clinical Study of NiCord® Presented at ASH 2018 Annual Meeting

Read More
Nov 28, 2018

Gamida Cell to Present at BMO Capital Markets Prescriptions for Success Healthcare Conference

Read More
Nov 01, 2018

Gamida Cell Announces New Translational Data for Nicord® to Be Presented at ASH 2018 Annual Meeting

Read More
Oct 26, 2018

Gamida Cell Announces Pricing of Initial Public Offering

Read More
Sep 18, 2018

Gamida Cell Strengthens Its Board of Directors with Appointment of Robert Blum as Chairman

Read More
Aug 06, 2018

Gamida Cell Expands its Leadership Team with the Appointment of Jaren Madden as Vice President, Investor Relations and Corporate Communications

Read More
Jul 23, 2018

Gamida Cell Expands Leadership Team with Appointments of Tzvi Palash as Chief Operating Officer and John Schick as Vice President of Market Access

Read More
Jul 17, 2018

Gamida Cell Receives Orphan Drug Designation from the FDA for NiCord® as a Treatment for Hematopoietic Stem Cell Transplantation

Read More
Jun 18, 2018

Gamida Cell to Present Preliminary Data from Ongoing Phase I NAM-NK Study at AACR International Meeting on Advances in Malignant Lymphoma

Read More
Apr 30, 2018

Gamida Cell to Present NiCord® Data at ISCT 2018 Annual Meeting

Read More
Apr 26, 2018

Gamida Cell Strengthens Leadership Team with Appointments of Josh Hamermesh as Chief Business Officer and Paul Nee as Vice President of Marketing

Read More
Mar 19, 2018

Gamida Cell to Present Immune Reconstitution Data for its NiCord® Program at the 2018 EBMT Annual Meeting

Read More
Mar 16, 2018

Gamida Cell to Present at Upcoming Investor Conferences

Read More
Mar 15, 2018

Gamida Cell Appoints Shai Lankry as Chief Financial Officer

Read More
Feb 20, 2018

Gamida Cell to Present Data from NiCord® Programs at the 2018 BMT Tandem Meetings

Read More
Jan 16, 2018

Gamida Cell Announces Initiation of a Phase I Study of NAM-NK Cells Immunotherapy Program for Non-Hodgkin Lymphoma and Multiple Myeloma

Read More
Dec 11, 2017

Gamida Cell Presents Data from Two Key Development Programs at the 2017 ASH Annual Meeting

Read More
Upcoming Events
More events are coming soon.

Investor & Media Contact

Jaren Irene Madden
Vice President of Investor Relations and Corporate Communications
Gamida Cell Ltd.